Biologics : Targets & Therapy最新文献_第2页

Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review. 基于抗体的小细胞肺癌治疗：叙述性综述。

IF 5.3

Biologics : Targets & Therapy Pub Date : 2025-04-15 eCollection Date: 2025-01-01 DOI: 10.2147/BTT.S500460

Andrea Torchia, Giuliana Ciappina, Maristella Giammaruco, Ilaria Monteferrante, Lorenza Landi, Federico Cappuzzo

{"title":"Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review.","authors":"Andrea Torchia, Giuliana Ciappina, Maristella Giammaruco, Ilaria Monteferrante, Lorenza Landi, Federico Cappuzzo","doi":"10.2147/BTT.S500460","DOIUrl":"https://doi.org/10.2147/BTT.S500460","url":null,"abstract":"Small-cell lung cancer (SCLC) is the most aggressive lung cancer, mostly diagnosed at advanced stage, and with few therapeutic options for patients failing the first-line treatment. Antibody-based therapies, such as antibody-drug conjugates and T-cell engagers, are emerging as a promising option in the treatment of various solid tumors, including SCLC. T-cell engagers are molecules able to trigger the T-cell-mediated tumor cell death binding, at the same time, a T-cell and a tumor cell target. Tarlatamab is a DLL3-directed bi-specific T-cell engager (BiTE) whose efficacy was evaluated in a Phase 2 study. Antibody-drug conjugates (ADC) consist of a tumor-directed monoclonal antibody conjugated to a cytotoxic payload able to selectively kill tumor cells through different mechanisms. Ifinatamab-deruxtecan is an anti-B7-H3 ADC showing efficacy in pretreated SCLC patients in a phase 2 clinical trial. Sacituzumab govitecan is a Trop-2-directed ADC already used in other tumor types and evaluated in SCLC in the phase 2 TROPiCS-03 trial, with positive results. Bispecific antibodies targeting VEGF and PD-(L)1 showed antitumor activity in phase 1 and 2 clinical trials. Other antibody-based agents are currently at an earlier phase of their clinical development and showed a promising activity. Novel antibody-based agents could potentially acquire a prominent role in the treatment of SCLC, a field with few therapeutic options. Direct comparisons with the current standard of care still lack, however Phase 3 trials are currently ongoing.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"189-199"},"PeriodicalIF":5.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing Monoclonal Antibody Manufacturing: Process Optimization, Cost Reduction Strategies, and Emerging Technologies. 推进单克隆抗体制造：工艺优化、成本降低策略和新兴技术。

IF 5.3

Biologics : Targets & Therapy Pub Date : 2025-04-09 eCollection Date: 2025-01-01 DOI: 10.2147/BTT.S515078

Ranjit Ranbhor

{"title":"Advancing Monoclonal Antibody Manufacturing: Process Optimization, Cost Reduction Strategies, and Emerging Technologies.","authors":"Ranjit Ranbhor","doi":"10.2147/BTT.S515078","DOIUrl":"https://doi.org/10.2147/BTT.S515078","url":null,"abstract":"Purpose: This review examines recent advances in monoclonal antibody (mAb) manufacturing, focusing on process optimization, cost reduction strategies, and emerging technologies. The analysis addresses critical challenges in current manufacturing processes while evaluating innovative solutions to improve production efficiency and economic viability.Methods: We conducted a comprehensive analysis of recent literature on mAb manufacturing, examining traditional batch processing, continuous processing, and hybrid systems. The review evaluates cost optimization strategies, including media development and process integration, while assessing the impact of emerging technologies, such as machine learning and advanced analytics, on manufacturing efficiency.Results: Recent studies demonstrate that continuous processing can achieve up to 35% cost savings compared to traditional batch processing to meet an annual production demand of 100-500 kg, though this gain diminishes at larger scales. Hybrid facilities show accelerated break-even points, reaching profitability 2-2.5 years earlier than traditional facilities. Advanced media optimization strategies, incorporating novel tripeptide delivery methods, have demonstrated up to 35% improvement in mAb titers. Integration of machine learning and advanced analytics has significantly enhanced process control and optimization capabilities.Conclusion: The evolution of mAb manufacturing technologies offers promising pathways for improving production efficiency and reducing costs. Scale-dependent considerations remain crucial in selecting optimal manufacturing strategies, while emerging technologies present new opportunities for process optimization. Future developments in continuous processing, advanced analytics, and cell line engineering will be essential in meeting growing global demand while ensuring economic viability and accessibility of mAb therapeutics.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"177-187"},"PeriodicalIF":5.3,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RNA Sequencing Identifies Novel Signaling Pathways and Potential Drug Target Genes Induced by FOSL1 in Glioma Progression and Stemness. RNA测序鉴定由FOSL1诱导的神经胶质瘤进展和干细胞的新信号通路和潜在药物靶基因。

IF 5.3

Biologics : Targets & Therapy Pub Date : 2025-04-05 eCollection Date: 2025-01-01 DOI: 10.2147/BTT.S509774

Shanchun Guo, Rajveer Sidhu, Vanajothi Ramar, Alyssa A Guo, Guangdi Wang, Mingli Liu

{"title":"RNA Sequencing Identifies Novel Signaling Pathways and Potential Drug Target Genes Induced by FOSL1 in Glioma Progression and Stemness.","authors":"Shanchun Guo, Rajveer Sidhu, Vanajothi Ramar, Alyssa A Guo, Guangdi Wang, Mingli Liu","doi":"10.2147/BTT.S509774","DOIUrl":"https://doi.org/10.2147/BTT.S509774","url":null,"abstract":"Background: Glioblastoma is a highly aggressive brain tumor, and the transition from the proneural to mesenchymal subtype is associated with more aggressive and therapy-resistant features. However, the signaling pathways and genes involved in this transition remain largely undefined.Methods: We utilized patient-derived xenograft (PDX) samples of glioblastoma, specifically PDX-L14, which exhibit both negative and overexpressed FOSL1 expression. mRNA expression profiles were assessed by RNA sequencing in these samples, followed by gene ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and Gene Set Enrichment Analysis (GSEA). Validation of the hub genes was performed using qPCR and immunohistochemistry assays.Results: Differentially expressed genes (DEGs) between FOSL1 overexpression groups were predominantly involved in ferroptosis, immune response, angiogenesis, vascular mimicry, autophagy, epithelial-mesenchymal transition (EMT), cancer cell stemness, temozolomide (TMZ) resistance, and NF-κB signaling. Downregulated DEGs were associated with TMZ resistance, glioma proliferation, RNA processing, and Wnt/β-catenin signaling. Key enrichment pathways, including NF-κB, Want, and BMP, are all critical for maintaining glioma stemness. FOSL1 was found to regulate RNA processing and ubiquitination. Notably, 8 upregulated (ITGA5, SDC1, PHLDB2, TNFRSF8, ADAM8, TLR7, STEAP3, and POU3F2) and 4 downregulated (IFIT1, FBXO16, ARL3, and BEX1) genes were identified, with implications for glioblastoma prognosis.Conclusion: This transcriptome investigation emphasizes the diverse functions of FOSL1 in different biological processes and signaling networks during the shift from proneural to mesenchymal state in glioblastoma.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"157-176"},"PeriodicalIF":5.3,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Telitacicept: A New Therapy for the Treatment of Optic Neuromyelitis Spectrum Disease Associated with Other Autoimmune Disorders. Telitacicept：一种治疗与其他自身免疫性疾病相关的视神经脊髓炎谱系疾病的新疗法

IF 5.3

Biologics : Targets & Therapy Pub Date : 2025-04-03 eCollection Date: 2025-01-01 DOI: 10.2147/BTT.S508605

Shaomin Zuo, Wenning Yang, Siyu Zhang, Shuyue Sun, Songke Lu, Chengcheng Lu, Wei Li

引用次数: 0

Evaluating Biosimilar Development Projects: An Analytical Framework Utilizing Net Present Value. 评价生物仿制药开发项目：利用净现值的分析框架。

IF 5.3

Biologics : Targets & Therapy Pub Date : 2025-03-25 eCollection Date: 2025-01-01 DOI: 10.2147/BTT.S514767

Ranjit Ranbhor, Priyanka Kulkarni

{"title":"Evaluating Biosimilar Development Projects: An Analytical Framework Utilizing Net Present Value.","authors":"Ranjit Ranbhor, Priyanka Kulkarni","doi":"10.2147/BTT.S514767","DOIUrl":"10.2147/BTT.S514767","url":null,"abstract":"Background: The increasing prominence of biosimilars in healthcare delivery has created the need for robust financial evaluation methods to assess development opportunities. Unlike traditional generic drugs, biosimilars require substantial investments ($100-250 million) and longer development timelines (6-8 years), necessitating sophisticated evaluation approaches.Methods: This study presents a comprehensive Net Present Value (NPV) analysis framework specifically designed for biosimilar development projects. Our framework incorporates key technical, regulatory, and commercial factors through a risk-adjusted NPV methodology, validated through case studies of three monoclonal antibody biosimilar development programs.Results: The analysis reveals that successful projects require minimum peak sales of $250-300 million to achieve a positive NPV, with market share and manufacturing efficiency serving as critical value drivers. Cost analysis shows that clinical development represents the largest share (57%) of total development costs.Conclusion: The framework demonstrates that early market entry, manufacturing optimization, and market share achievement are key success factors, whereas technical complexity and competitive intensity significantly influence risk-adjusted returns.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"125-135"},"PeriodicalIF":5.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet-Derived Growth Factor as Biomarker of Clinical Outcome for Autologous Platelet Concentrate Therapy in Grade I Knee Osteoarthritis. 血小板衍生生长因子作为自体浓缩血小板治疗I级膝骨关节炎临床结果的生物标志物

IF 5.3

Biologics : Targets & Therapy Pub Date : 2025-03-25 eCollection Date: 2025-01-01 DOI: 10.2147/BTT.S500522

Michele Francesco Di Tolla, Serena Romano, Pietro Vassetti, Domenico Perugini, Immacolata Filoso, Serena Cabaro, Giusy Ferraro, Francesco Oriente, Giuseppe Perruolo, Flora Arvonio, Vittoria D'Esposito, Pietro Formisano

{"title":"Platelet-Derived Growth Factor as Biomarker of Clinical Outcome for Autologous Platelet Concentrate Therapy in Grade I Knee Osteoarthritis.","authors":"Michele Francesco Di Tolla, Serena Romano, Pietro Vassetti, Domenico Perugini, Immacolata Filoso, Serena Cabaro, Giusy Ferraro, Francesco Oriente, Giuseppe Perruolo, Flora Arvonio, Vittoria D'Esposito, Pietro Formisano","doi":"10.2147/BTT.S500522","DOIUrl":"10.2147/BTT.S500522","url":null,"abstract":"Introduction: Autologous platelet concentrates (APC) are widely used in the infiltrative treatment of knee osteoarthritis (OA) to enhance tissue healing and relieve pain. Aim of this study was to identify predictive biomarkers for clinical outcomes in patients with grade I knee OA.Methods: A panel of growth factors (GFs) and cytokines was determined in peripheral blood (PB) and APC. The Numeric Pain Rating Scale (NPRS) was used as a clinical readout before and after the APC infiltration.Results: A lower white blood cell (WBC) count and higher Monocyte-chemoattractant Protein-1 levels in PB were associated with APC-induced pain relief. Platelet-derived Growth Factor (PDGF) levels in APC were significantly higher in OA patients displaying a larger NPRS reduction, independent of platelet count. Finally, the simultaneous determination of PDGF, Vascular Endothelial Growth Factor, and Macrophage Inflammatory Protein-1α in APC discriminated OA patients with very poor or no response.Conclusion: Platelet-released GFs rather than platelet counts may predict clinical outcomes in grade 1 knee OA.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"137-147"},"PeriodicalIF":5.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting DNA Topoisomerase IIα in Retinoblastoma: Implications in EMT and Therapeutic Strategies. 靶向DNA拓扑异构酶i α治疗视网膜母细胞瘤：EMT的意义和治疗策略。

IF 5.3

Biologics : Targets & Therapy Pub Date : 2025-03-18 eCollection Date: 2025-01-01 DOI: 10.2147/BTT.S499314

Qingquan Wei, Nan Lin, Li Wang

{"title":"Targeting DNA Topoisomerase IIα in Retinoblastoma: Implications in EMT and Therapeutic Strategies.","authors":"Qingquan Wei, Nan Lin, Li Wang","doi":"10.2147/BTT.S499314","DOIUrl":"10.2147/BTT.S499314","url":null,"abstract":"Background: This study investigates the role of DNA topoisomerase IIα (TOP2A) in retinoblastoma (RB), focusing on its involvement in epithelial-mesenchymal transition (EMT) and the potential of TOP2A inhibition as a therapeutic strategy.Methods: We analyzed TOP2A expression in RB tissues using public gene expression databases (GSE97508, GSE110811, and GSE172170) and conducted functional assays in human RB cell lines (Y79 and WERI-Rb-1) modified to knock down or overexpress TOP2A. Assessments included cell proliferation, migration, invasion, and EMT marker expression via RT-PCR and Western blot. Additionally, we evaluated the effects of TOP2A modulation in subcutaneous and liver metastasis mouse xenograft models.Results: TOP2A was significantly overexpressed in RB tissues (p < 0.0001). In vitro, TOP2A knockdown inhibited RB cell proliferation, migration, and invasion, and reversed EMT marker expression (p < 0.05), while TOP2A overexpression enhanced these oncogenic processes. In vivo, TOP2A knockdown or inhibition significantly reduced tumor growth and metastasis in both subcutaneous and liver metastasis models (p < 0.05). Combination therapy with TOP2A and EMT inhibitors further enhanced anti-tumor effects, significantly reducing tumor burden and metastatic lesions (p < 0.01).Conclusion: TOP2A is pivotal in RB pathogenesis and progression, primarily by regulating EMT. Its inhibition not only curtails RB cell proliferation and metastasis but also reverses EMT, underscoring its potential as a therapeutic target. This study lays the groundwork for further exploration of TOP2A-targeted therapies in RB.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"113-123"},"PeriodicalIF":5.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer. 早期乳腺癌内分泌治疗的升级和降级策略。

IF 5.3

Biologics : Targets & Therapy Pub Date : 2025-03-13 eCollection Date: 2025-01-01 DOI: 10.2147/BTT.S508634

Tamer Al-Batsh, Nayef Abdel-Razeq, Yosra Al-Masri, Osama El-Khatib, Baha Sharaf, Faris Tamimi, Hikmat Abdel-Razeq

{"title":"Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer.","authors":"Tamer Al-Batsh, Nayef Abdel-Razeq, Yosra Al-Masri, Osama El-Khatib, Baha Sharaf, Faris Tamimi, Hikmat Abdel-Razeq","doi":"10.2147/BTT.S508634","DOIUrl":"10.2147/BTT.S508634","url":null,"abstract":"Although adjuvant endocrine therapy (ET) greatly lowers the risk of recurrence and mortality in hormone receptor (HR)-positive early-stage breast cancer (EBC), more than 20% of patients may experience relapses within 10 years, often manifesting as incurable distant metastases. To improve outcomes, ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa) added to tamoxifen or aromatase inhibitors like exemestane have shown significant disease-free survival (DFS) and, in some cases, overall survival (OS) benefits. CDK4/6 inhibitors, a cornerstone in metastatic HR-positive, HER2-negative breast cancer (MBC), are now being explored in EBC. Trials with abemaciclib and ribociclib have shown promise in high-risk EBC. For BRCA-mutant patients, the PARP inhibitor olaparib, as demonstrated in the OlympiA trial, significantly improved invasive DFS and OS when used as adjuvant therapy for one year. Conversely, de-escalation strategies are also emerging. Recent studies suggest that younger premenopausal women with low-risk disease may safely interrupt ET after 18-30 months to pursue pregnancy. Additionally, genomic tumor profiling is widely utilized to decide on aggressiveness of adjuvant therapy of EBC. These advancements reflect a shift toward personalized adjuvant therapy, integrating targeted treatments like CDK4/6 inhibitors and PARP inhibitors, optimizing ET with OFS, and balancing efficacy with quality of life through de-escalation strategies. This tailored approach aims to improve long-term outcomes for HR-positive EBC patients.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"97-111"},"PeriodicalIF":5.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement. 循环PGC-1α和MOTS-c肽作为主动脉瓣置换术患者潜在的线粒体生物标志物

IF 5.3

Biologics : Targets & Therapy Pub Date : 2025-03-13 eCollection Date: 2025-01-01 DOI: 10.2147/BTT.S504289

María J Sánchez-Quintero, Andrea Iboleón, Laura Martín Chaves, Bárbara Pozo Vilumbrales, Ada D M Carmona-Segovia, Pilar Martínez López, Miguel Romero-Cuevas, Jorge Rodríguez-Capitán, Víctor M Becerra-Muñoz, Francisco Javier Pavón-Morón, Mora Murri

{"title":"Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement.","authors":"María J Sánchez-Quintero, Andrea Iboleón, Laura Martín Chaves, Bárbara Pozo Vilumbrales, Ada D M Carmona-Segovia, Pilar Martínez López, Miguel Romero-Cuevas, Jorge Rodríguez-Capitán, Víctor M Becerra-Muñoz, Francisco Javier Pavón-Morón, Mora Murri","doi":"10.2147/BTT.S504289","DOIUrl":"10.2147/BTT.S504289","url":null,"abstract":"Purpose: Aortic valve disease (AVD) is a common condition that leads to pressure and/or volume overload in the left ventricle. Aortic valve replacement is the standard treatment, as no pharmacological therapies are currently available. The incidence of AVD is increasing in developed countries, making the discovery of new biomarkers for early detection crucial. The importance of mitochondria in heart function is well established, and various cardiovascular pathologies are associated with mitochondrial dysfunction. In this cross-sectional study, we evaluated for the first time the role of mitochondria in AVD, aiming to identify new pathways involved in the disease and discover potential biomarkers.Patients and methods: We recruited 17 patients diagnosed with AVD and scheduled for aortic valve replacement, and 22 healthy controls. Plasma levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) and mitochondrial open reading frame of the 12S rRNA type-c peptide (MOTS-c) were measured by ELISA.Results: We observed significantly reduced levels of both proteins in patients, suggesting that substantial mitochondrial dysfunction occurs in AVD patients, independent of sex or age, but directly related to the disease.Conclusion: Mitochondria may represent a promising target for studying new pathways involved in AVD. We propose PGC1α and MOTS-c as potential plasma biomarkers for AVD detection. Further studies, including early-stage patients, are necessary to confirm the significance of our findings.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"87-96"},"PeriodicalIF":5.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Mechanisms and Therapeutic Implications of PI3K Signaling in Airway Inflammation and Remodeling in Asthma. PI3K信号在哮喘气道炎症和重塑中的作用机制及其治疗意义。

IF 5.3

Biologics : Targets & Therapy Pub Date : 2025-03-07 eCollection Date: 2025-01-01 DOI: 10.2147/BTT.S497622

Bangguo Song, Jihong Hu, Shupeng Chen, Yang Zhang

{"title":"The Mechanisms and Therapeutic Implications of PI3K Signaling in Airway Inflammation and Remodeling in Asthma.","authors":"Bangguo Song, Jihong Hu, Shupeng Chen, Yang Zhang","doi":"10.2147/BTT.S497622","DOIUrl":"10.2147/BTT.S497622","url":null,"abstract":"Bronchial asthma is a complex and heterogeneous disease with ongoing airway inflammation and increased airway responsiveness. Key characteristics of the disease include persistent airway inflammation, airway hyperresponsiveness, and airway remodeling. Asthma's chronic and recurrent characteristics contribute to airway remodeling and inflammation, which can exacerbate lung damage. Presently, inflammation is predominantly managed with corticosteroids, yet there is a notable absence of treatments specifically addressing airway remodeling. The phosphoinositide 3-kinase (PI3K) signaling pathway is integral to the processes of inflammation, airway remodeling, and immune responses. Pharmacological agents targeting this pathway are currently undergoing clinical evaluation. This review elucidates the role of PI3K in the immune responses, airway inflammation, and remodeling associated with asthma, examining its underlying mechanisms. Furthermore, we synthesize the existing literature on the therapeutic potential of PI3K inhibitors for asthma management, emphasizing immune modulation, airway inflammation, and remodeling, including drug development and ongoing clinical trials. Lastly, we explore how various PI3K-targeted therapies may enhance efficacy and improve tolerance.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"73-86"},"PeriodicalIF":5.3,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0